GSA Capital Partners LLP Decreases Position in Biohaven Ltd. (NYSE:BHVN)

GSA Capital Partners LLP decreased its position in Biohaven Ltd. (NYSE:BHVN) by 70.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,609 shares of the company’s stock after selling 11,124 shares during the period. GSA Capital Partners LLP’s holdings in Biohaven were worth $230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock valued at $345,031,000 after buying an additional 4,650,702 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Biohaven by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock valued at $183,050,000 after acquiring an additional 212,699 shares during the period. Farallon Capital Management LLC lifted its holdings in Biohaven by 181.4% during the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock valued at $78,028,000 after purchasing an additional 1,449,000 shares during the last quarter. Armistice Capital LLC boosted its position in Biohaven by 74.8% during the second quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after purchasing an additional 597,705 shares during the period. Finally, ARS Investment Partners LLC increased its stake in shares of Biohaven by 47.8% in the second quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock worth $32,645,000 after purchasing an additional 304,141 shares in the last quarter. 88.78% of the stock is owned by institutional investors.

Biohaven Price Performance

Shares of BHVN opened at $45.59 on Monday. Biohaven Ltd. has a 1-year low of $26.80 and a 1-year high of $62.21. The company has a market capitalization of $4.61 billion, a P/E ratio of -4.88 and a beta of 1.31. The firm’s 50 day simple moving average is $49.10 and its 200 day simple moving average is $41.10.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). On average, equities analysts anticipate that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Insider Transactions at Biohaven

In related news, Director Gregory Bailey bought 5,000 shares of the stock in a transaction dated Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, with a total value of $220,950.00. Following the purchase, the director now owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. The trade was a 0.31 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John W. Childs purchased 21,052 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was bought at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the purchase, the director now directly owns 21,052 shares in the company, valued at approximately $999,970. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 16.00% of the company’s stock.

Analyst Upgrades and Downgrades

BHVN has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research note on Wednesday, October 23rd. Royal Bank of Canada dropped their target price on Biohaven from $68.00 to $66.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 13th. Robert W. Baird raised their price target on Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Bank of America boosted their price objective on Biohaven from $52.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, William Blair upgraded Biohaven to a “strong-buy” rating in a research note on Friday, August 30th. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $63.42.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.